Yep, Victoza® is now officially available in Spain. As of the 1st September you can purchase the medication over the counter if you are unable to get a prescription for it. However I am told that the drug has been used in certain clinical environments mainly hospital including my local one; Hospital de Torrevieja. If [...]
Tag Archives | type 2
Linagliptin (Trajenta ) Type 2 Diabetes Drug Now Approved in Europe
Linagliptin, is currently being sold in the United States under the trade name Tradjenta and it now has European approval. Indianapolis-based Lilly and Boehringer, a German company, said the European Commission granted marketing authorization for 5-milligram tablets to be used alone or in combination with other treatments. Lilly and Boehringer entered an agreement earlier this [...]
Victoza Still Not Available in Spain
Confirmation that Victoza is available in Spain was announced this week. Hi, just a quick update to let folks know that as yet Victoza has not been given approval by the relevant governmental agencies here in Spain. Off course as soon as we have further details they will be published here. Victoza en España! Ya está [...]
Novo Nordisk’s Victoza® Receives FDA Approval for Adults With Type 2 Diabetes
Novo Nordisk announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza®, the first once-daily human glucagon-like injection for the treatment of type 2 diabetes. Victoza is indicated as an addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
One in five hospital patients has diabetes
One in five hospital patients now suffers from diabetes, according to a national audit which reveals the devastating impact of changes in British lifestyles.
UK Spend 600 Million Pounds On Prescribed Diabetes Medication
More money is spent on diabetes medication in primary care than on treatments for any other condition, with almost £600 million of medicines prescribed by doctors last year, according to a report.
Join us on Facebook!
Advocating @
